Aileron Therapeutics (ALRN) received a Buy rating and a $5.00 price target from Canaccord Genuity analyst John Newman yesterday. The company’s shares closed last Thursday at $0.32, close to its 52-week low of $0.25.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 11.6% and a 41.3% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Atara Biotherapeutics.
Aileron Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00, which is an 1125.1% upside from current levels. In a report issued on March 31, H.C. Wainwright also maintained a Buy rating on the stock with a $3.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.89 and a one-year low of $0.25. Currently, Aileron Therapeutics has an average volume of 234.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.
